September 6, 2019
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) retained the top slot in the Japan drug sales ranking in August, hauling in revenues of 12 billion yen on an NHI price basis, according to a monthly snapshot report released by market research firm...read more